Navigation Links
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
Date:4/28/2009

    FDA confirms durable pain palliation as an acceptable primary endpoint
    for a regulatory submission in support of market approval

BOTHELL, WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a second Phase 3 registration trial of OGX-011, its lead product candidate targeting castrate resistant prostate cancer (CRPC), via the Special Protocol Assessment (SPA) process. The FDA has agreed that the design and planned analysis of our Phase 3 trial featuring durable pain palliation as the primary endpoint adequately addresses the objectives necessary to support a regulatory submission.

"We have now received confirmations on two separate Phase 3 trial designs from the FDA via the SPA process, each in second-line treatment of advanced prostate cancer," said Scott Cormack, President and CEO of OncoGenex Pharmaceuticals. "One trial design evaluates overall survival benefit while the second trial design evaluates reduction in pain as the primary endpoint. Having evaluated both of these endpoints in our Phase 2 trials, we are well positioned to re-evaluate each of these endpoints in larger Phase 3 registration trials."

"The FDA's acknowledgement of pain in addition to survival as key endpoints for market approval supports the basis of our OGX-011 development program for advanced prostate cancer," added Cormack. "Although we observed a positive effect on PSA in our Phase 2 trials of OGX-011, we recognize that PSA response has not been shown to correlate to a clinical benefit and therefore is not an acceptable endpoint for FDA approval. Our focus remains on survival and pain palliation, both endpoints that FDA has confirmed are appropriate for marketing approval, and both endp
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Wellinton, Florida (PRWEB) , ... September 02, 2015 ... ... has been treated and managed with the use of special anti-vascular endothelial growth ... occurs in many more patients, currently does not have a scientific protocol for ...
(Date:9/2/2015)... 2015 Biovista Inc. is glad ... 2015 BeHEARD science challenge, a global competition hosted by ... access to the latest life science innovations and technologies. ... pathway analytics capability to support Steven Laffoon ... study of Niemann-Pick Disease Type A (NPA), a rare ...
(Date:9/2/2015)... Aytu BioScience, Inc. (OTCQB: AYTU), a specialty ... related conditions, announced today that it has closed the ... financing, raising a total of $5.175 million, which includes ... Josh Disbrow , Chief Executive Officer ... intended to be used to conduct clinical studies for ...
(Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 /PRNewswire/ ... Sponsoring der Gewinner des Wettbewerbs BeHEARD von 2015 ... einen internationalen vom Rare Genomics Institute. ... Wirksamkeit von Medikamenten für die Behandlung anderer Krankheiten ... wurde, Steven Laffoon und sein Team ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... Pharmaceuticals, Inc. (NYSE Amex: ANX ) today ... ended December 31, 2008."2008 was a transition year for ... focused on lower-risk reformulations of previously-approved drugs. We achieved ... the difficult economic environment, we were unable to attract ...
... Insmed Inc. (Nasdaq: INSM ), a developer of ... March 23, 2009, NASDAQ issued a notice further extending the ... price and those rules requiring a minimum market value of ... effect through Friday, July 17, 2009, and the original rules ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... patient enrolment in its U.K. clinical trial to ... REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients ... neck. The principal investigators are Dr. Johann de ...
Cached Biology Technology:ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 7Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3
(Date:8/10/2015)... and TELTOW, Germany , August 10, ... (SMI), a world leader in Eye Tracking Technology for ... its OEM Eye Tracking Platform for integration into all ... contains reference designs for seamless integration of eye tracking ... reality HMDs and augmented reality smart glasses. Omnivision,s leading ...
(Date:8/5/2015)... -- According to a new market research ... Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, Defense ... 2020", published by MarketsandMarkets, defines and segments the Physical ... The global PIAM Market is estimated to grow from ... at a CAGR of 14.9 % from 2014 to ...
(Date:8/3/2015)... Synaptics, Inc. (Nasdaq: SYNA ), the ... members of the executive management team will present to ... Leadership Forum on Tuesday, August 11, 2015 at 1:00 ... the Sonnenalp Resort in Vail, CO. ... information. An audio webcast of the event will be ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... of new coal-fired power plants in the United States ... due to the high cost of the requirement ... of carbon dioxide, an important greenhouse gas. But an ... construction moving again, allowing the nation to fend off ...
... by researchers at UC Davis Medical Center suggests that ... be a result of their brains not telling their ... blood oxygen levels are more common than we thought ... Masud Seyal, a professor of neurology at UC Davis ...
... , Thanks to our ability to learn and to remember, we ... of. However, we are only just beginning to get the gist ... or forgets something. What we do know is that changes in ... these structural changes account for that well-known phenomenon that it is ...
Cached Biology News:MIT: A quicker, easier way to make coal cleaner 2MIT: A quicker, easier way to make coal cleaner 3Drops in blood oxygen levels may be key to sudden death in some epilepsy patients 2Drops in blood oxygen levels may be key to sudden death in some epilepsy patients 3Forgotten but not gone -- how the brain takes care of things 2Forgotten but not gone -- how the brain takes care of things 3
... The wide mini ReadySub-Cell GT cell and ... horizontal gel electrophoresis of nucleic acids in agarose ... buffer tank, lid with cables and electrodes, and ... and 220-240 V, provides output of 10-300 V, ...
... and you reduce the chance of error. ... 8000. Developed using Beckman Coulters extensive experience ... electrophoresis technology, the CEQ 8000 is a ... automatically fills the capillary array with a ...
... 2000 Capillary Electrophoresis System uses revolutionary ... electrophoresis (SPE), urine protein electrophoresis and ... accurate analysis. The system is truly ... and no staining to process patient ...
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
Biology Products: